


MK-4541

Cat. No.:	HY-125065
CAS No.:	796885-38-6
Molecular Formula:	C ₂₂ H ₃₁ F ₃ N ₂ O ₃
Molecular Weight:	428.49
Target:	Androgen Receptor; 5 alpha Reductase
Pathway:	Vitamin D Related/Nuclear Receptor; Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	MK-4541 is an orally active and selective androgen receptor (AR) modulator. MK-4541 acts as an antagonist to inhibit 5 α -reductase. MK-4541 inhibits proliferation and induces apoptosis in AR positive prostate cancer cells. MK-4541 significantly inhibited the growth of R3327-G prostate tumors in xenograft mouse model ^[1] .								
In Vivo	<p>MK-4541 (100 mg/kg; p.o.; 5 times per week for 5 weeks) inhibits prostate tumor growth in athymic nude mice bearing R-3327-G cells^[1].</p> <p>MK-4541 (100 mg/kg, 200 mg/kg; p.o.; 5 times per week for 5 weeks) exhibits anti-androgen effects on the seminal vesicles, reduces plasma testosterone concentrations in intact males, and inhibits Ki67 expression^[1].</p> <p>MK-4541 (15 mg/kg, 50 mg/kg; p.o.; 5 times per week for 8 weeks) causes the loss of musculoskeletal mass and function in adult castrated mice^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Animal Model:</td> <td>R3327-G prostate tumors in xenograft mouse model^[1]</td> </tr> <tr> <td>Dosage:</td> <td>25 mg/kg, 50 mg/kg, 100 mg/kg, 200 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Oral gavage; once daily, 5 times per week for 5 weeks</td> </tr> <tr> <td>Result:</td> <td>Significantly inhibited tumor growth at 100 mg/kg, as well as reducing plasma testosterone concentration and Ki67 expression.</td> </tr> </table>	Animal Model:	R3327-G prostate tumors in xenograft mouse model ^[1]	Dosage:	25 mg/kg, 50 mg/kg, 100 mg/kg, 200 mg/kg	Administration:	Oral gavage; once daily, 5 times per week for 5 weeks	Result:	Significantly inhibited tumor growth at 100 mg/kg, as well as reducing plasma testosterone concentration and Ki67 expression.
Animal Model:	R3327-G prostate tumors in xenograft mouse model ^[1]								
Dosage:	25 mg/kg, 50 mg/kg, 100 mg/kg, 200 mg/kg								
Administration:	Oral gavage; once daily, 5 times per week for 5 weeks								
Result:	Significantly inhibited tumor growth at 100 mg/kg, as well as reducing plasma testosterone concentration and Ki67 expression.								

REFERENCES

[1]. Chisamore MJ, et al. A novel selective androgen receptor modulator (SARM) MK-4541 exerts anti-androgenic activity in the prostate cancer xenograft R-3327G and anabolic activity on skeletal muscle mass & function in castrated mice. *J Steroid Biochem Mol Biol.* 2016 Oct;163:88-97.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA